The North America & Europe infectious disease molecular diagnostics market size was estimated at USD 6.09 billion in 2025 and is projected to reach USD 10.77 billion by 2033, growing at a CAGR of 7.44% from 2026 to 2033. The market is driven by the increasing burden of infectious diseases, including respiratory infections, HIV, and hospital-acquired infections, which is accelerating demand for rapid and highly accurate diagnostic solutions. ![North American & European Infectious Disease Molecular Diagnostics Market]( "North American & European Infectious Disease Molecular Diagnostics Market")
Growth is further supported by continuous advancements in molecular technologies such as PCR, multiplex assays, and next-generation sequencing, along with strong healthcare infrastructure and government investments in disease surveillance and early detection systems.
Growth is further supported by continuous advancements in molecular technologies such as PCR, multiplex assays, and next-generation sequencing, along with strong healthcare infrastructure and government investments in disease surveillance and early detection systems.
North America & Europe Infectious Disease Molecular Diagnostics Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, the analyst has segmented the North America & Europe infectious disease molecular diagnostics market on the basis of test category, application customer type, setting-based, throughput, algorithm-based, region:Application Outlook (Revenue, USD Million, 2021-2033)
- Gastrointestinal Infections
- Syndromic Test
- Targeted Test
- Point of Care Molecular Diagnostics
- Respiratory Infection Testing
- Syndromic Test
- Targeted Test
- Point of Care Molecular Diagnostics
- Hospital-Acquired Infections (HAIs)
- Disease Type
- Methicillin-Resistant Staphylococcus Aureus (MRSA)
- Clostridioides difficile Infection (CDI)
- Carbapenem-Resistant Enterobacteriaceae (CRE)
- Vancomycin-Resistant Enterococci (VRE)
- Other Nosocomial Pathogens
- Test Category
- Syndromic Test
- Targeted Test
- Point of Care Molecular Diagnostics
- Bloodstream Infections
- Syndromic Test
- Targeted Test
- Point of Care Molecular Diagnostics
- Meningitis / CNS Infections
- Vector-Borne Infections
- Disease Type
- Dengue
- Zika
- Lyme Disease
- West Nile Virus
- Chikungunya
- Other Vector-Borne Infections
Test Category Outlook (Revenue, USD Million, 2021-2033)
- Syndromic Test
- Targeted Test
- Point of Care Molecular Diagnostics
Customer Type Outlook (Revenue, USD Million, 2021-2033)
- Hospital Laboratories
- Reference Laboratories
- Academic Centers
- Regional Hospitals
- Children’s Hospital
- Other
Setting-Based Outlook (Revenue, USD Million, 2021-2033)
- Central Laboratories
- Near-Patient Settings
Throughput Outlook (Revenue, USD Million, 2021-2033)
- Low-volume Laboratories
- Mid-volume Laboratories
- High-volume Laboratories
Algorithm-based Outlook (Revenue, USD Million, 2021-2033)
- Frontline Screening
- Reflex/Algorithm-driven Testing
- Syndromic Testing
- Targeted Confirmation
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Application
1.2.2. Test Category
1.2.3. Customer Type
1.2.4. Setting-based
1.2.5. Throughput
1.2.6. Algorithm-based
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
1.2. Segment Definitions
1.2.1. Application
1.2.2. Test Category
1.2.3. Customer Type
1.2.4. Setting-based
1.2.5. Throughput
1.2.6. Algorithm-based
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. North America and Europe Infectious Disease Molecular Diagnostics Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Rising burden of infectious diseases & antimicrobial resistance (amr)
3.2.1.2. Rapid adoption of syndromic molecular testing
3.2.1.3. Shift toward decentralized & near-patient testing
3.2.2. Market Restraint Analysis
3.2.2.1. High cost of molecular testing & infrastructure dependence
3.2.2.2. Stringent and evolving regulatory requirements (FDA & IVDR impact)
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Rising burden of infectious diseases & antimicrobial resistance (amr)
3.2.1.2. Rapid adoption of syndromic molecular testing
3.2.1.3. Shift toward decentralized & near-patient testing
3.2.2. Market Restraint Analysis
3.2.2.1. High cost of molecular testing & infrastructure dependence
3.2.2.2. Stringent and evolving regulatory requirements (FDA & IVDR impact)
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis
Chapter 4. North America and Europe Infectious Disease Molecular Diagnostics Market: Application Business Analysis
4.1. Application Market Share, 2025 & 2033
4.2. Application Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
4.4. Gastrointestinal Infections
4.4.1. Gastrointestinal Infections Market, 2021 - 2033 (USD Million)
4.4.1.1. Test Category
4.4.1.1.1. Test Category Market, 2021 - 2033 (USD Million)
4.4.1.1.1.1. Syndromic Test
4.4.1.1.1.1.1. Syndromic Test Market, 2021 - 2033 (USD Million)
4.4.1.1.1.2. Targeted Test
4.4.1.1.1.2.1. Targeted Test Market, 2021 - 2033 (USD Million)
4.4.1.1.1.3. Point of Care Molecular Diagnostics
4.4.1.1.1.3.1. Point of Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
4.5. Respiratory Infection Testing
4.5.1. Respiratory Infection Testing Market, 2021 - 2033 (USD Million)
4.5.1.1. Test Category
4.5.1.1.1. Test Category Market, 2021 - 2033 (USD Million)
4.5.1.1.1.1. Syndromic Test
4.5.1.1.1.1.1. Syndromic Test Market, 2021 - 2033 (USD Million)
4.5.1.1.1.2. Targeted Test
4.5.1.1.1.2.1. Targeted Test Market, 2021 - 2033 (USD Million)
4.5.1.1.1.3. Point of Care Molecular Diagnostics
4.5.1.1.1.3.1. Point of Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
4.6. Hospital-Acquired Infections (HAIs)
4.6.1. Hospital-Acquired Infections (HAIs) Market, 2021 - 2033 (USD Million)
4.6.1.1. Disease Type
4.6.1.1.1. Disease Type Market, 2021 - 2033 (USD Million)
4.6.1.1.1.1. Methicillin-Resistant Staphylococcus Aureus (MRSA)
4.6.1.1.1.1.1. Methicillin-Resistant Staphylococcus Aureus (MRSA) Market, 2021 - 2033 (USD Million)
4.6.1.1.1.2. Clostridioides Difficile Infection (CDI)
4.6.1.1.1.2.1. Clostridioides difficile Infection (CDI) Market, 2021 - 2033 (USD Million)
4.6.1.1.1.3. Carbapenem-Resistant Enterobacteriaceae (CRE)
4.6.1.1.1.3.1. Carbapenem-Resistant Enterobacteriaceae (CRE) Market, 2021 - 2033 (USD Million)
4.6.1.1.1.4. Vancomycin-Resistant Enterococci (VRE)
4.6.1.1.1.4.1. Vancomycin-Resistant Enterococci (VRE) Market, 2021 - 2033 (USD Million)
4.6.1.1.1.5. Other Nosocomial Pathogens
4.6.1.1.1.5.1. Other Nosocomial Pathogens Market, 2021 - 2033 (USD Million)
4.6.1.2. Test Category
4.6.1.2.1. Test Category Market, 2021 - 2033 (USD Million)
4.6.1.2.1.1. Syndromic Test
4.6.1.2.1.1.1. Syndromic Test Market, 2021 - 2033 (USD Million)
4.6.1.2.1.2. Targeted Test
4.6.1.2.1.2.1. Targeted Test Market, 2021 - 2033 (USD Million)
4.6.1.2.1.3. Point of Care Molecular Diagnostics
4.6.1.2.1.3.1. Point of Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
4.7. Bloodstream Infections
4.7.1. Bloodstream Infections Market, 2021 - 2033 (USD Million)
4.7.1.1. Test Category
4.7.1.1.1. Test Category Market, 2021 - 2033 (USD Million)
4.7.1.1.1.1. Syndromic Test
4.7.1.1.1.1.1. Syndromic Test Market, 2021 - 2033 (USD Million)
4.7.1.1.1.2. Targeted Test
4.7.1.1.1.2.1. Targeted Test Market, 2021 - 2033 (USD Million)
4.7.1.1.1.3. Point of Care Molecular Diagnostics
4.7.1.1.1.3.1. Point of Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
4.8. Meningitis / CNS Infections
4.8.1. Meningitis / CNS Infections Market, 2021 - 2033 (USD Million)
4.9. Vector-Borne Infections
4.9.1. Vector-Borne Infections Market, 2021 - 2033 (USD Million)
4.9.1.1. Disease Type
4.9.1.1.1. Disease Type Market, 2021 - 2033 (USD Million)
4.9.1.1.1.1. Dengue
4.9.1.1.1.1.1. Dengue Market, 2021 - 2033 (USD Million)
4.9.1.1.1.2. Zika
4.9.1.1.1.2.1. Zika Market, 2021 - 2033 (USD Million)
4.9.1.1.1.3. Lyme Disease
4.9.1.1.1.3.1. Lyme Disease Market, 2021 - 2033 (USD Million)
4.9.1.1.1.4. West Nile Virus
4.9.1.1.1.4.1. West Nile Virus Market, 2021 - 2033 (USD Million)
4.9.1.1.1.5. Chikungunya
4.9.1.1.1.5.1. Chikungunya Market, 2021 - 2033 (USD Million)
4.9.1.1.1.6. Other Vector-Borne Infections
4.9.1.1.1.6.1. Other Vector-Borne Infections Market, 2021 - 2033 (USD Million)
4.2. Application Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
4.4. Gastrointestinal Infections
4.4.1. Gastrointestinal Infections Market, 2021 - 2033 (USD Million)
4.4.1.1. Test Category
4.4.1.1.1. Test Category Market, 2021 - 2033 (USD Million)
4.4.1.1.1.1. Syndromic Test
4.4.1.1.1.1.1. Syndromic Test Market, 2021 - 2033 (USD Million)
4.4.1.1.1.2. Targeted Test
4.4.1.1.1.2.1. Targeted Test Market, 2021 - 2033 (USD Million)
4.4.1.1.1.3. Point of Care Molecular Diagnostics
4.4.1.1.1.3.1. Point of Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
4.5. Respiratory Infection Testing
4.5.1. Respiratory Infection Testing Market, 2021 - 2033 (USD Million)
4.5.1.1. Test Category
4.5.1.1.1. Test Category Market, 2021 - 2033 (USD Million)
4.5.1.1.1.1. Syndromic Test
4.5.1.1.1.1.1. Syndromic Test Market, 2021 - 2033 (USD Million)
4.5.1.1.1.2. Targeted Test
4.5.1.1.1.2.1. Targeted Test Market, 2021 - 2033 (USD Million)
4.5.1.1.1.3. Point of Care Molecular Diagnostics
4.5.1.1.1.3.1. Point of Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
4.6. Hospital-Acquired Infections (HAIs)
4.6.1. Hospital-Acquired Infections (HAIs) Market, 2021 - 2033 (USD Million)
4.6.1.1. Disease Type
4.6.1.1.1. Disease Type Market, 2021 - 2033 (USD Million)
4.6.1.1.1.1. Methicillin-Resistant Staphylococcus Aureus (MRSA)
4.6.1.1.1.1.1. Methicillin-Resistant Staphylococcus Aureus (MRSA) Market, 2021 - 2033 (USD Million)
4.6.1.1.1.2. Clostridioides Difficile Infection (CDI)
4.6.1.1.1.2.1. Clostridioides difficile Infection (CDI) Market, 2021 - 2033 (USD Million)
4.6.1.1.1.3. Carbapenem-Resistant Enterobacteriaceae (CRE)
4.6.1.1.1.3.1. Carbapenem-Resistant Enterobacteriaceae (CRE) Market, 2021 - 2033 (USD Million)
4.6.1.1.1.4. Vancomycin-Resistant Enterococci (VRE)
4.6.1.1.1.4.1. Vancomycin-Resistant Enterococci (VRE) Market, 2021 - 2033 (USD Million)
4.6.1.1.1.5. Other Nosocomial Pathogens
4.6.1.1.1.5.1. Other Nosocomial Pathogens Market, 2021 - 2033 (USD Million)
4.6.1.2. Test Category
4.6.1.2.1. Test Category Market, 2021 - 2033 (USD Million)
4.6.1.2.1.1. Syndromic Test
4.6.1.2.1.1.1. Syndromic Test Market, 2021 - 2033 (USD Million)
4.6.1.2.1.2. Targeted Test
4.6.1.2.1.2.1. Targeted Test Market, 2021 - 2033 (USD Million)
4.6.1.2.1.3. Point of Care Molecular Diagnostics
4.6.1.2.1.3.1. Point of Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
4.7. Bloodstream Infections
4.7.1. Bloodstream Infections Market, 2021 - 2033 (USD Million)
4.7.1.1. Test Category
4.7.1.1.1. Test Category Market, 2021 - 2033 (USD Million)
4.7.1.1.1.1. Syndromic Test
4.7.1.1.1.1.1. Syndromic Test Market, 2021 - 2033 (USD Million)
4.7.1.1.1.2. Targeted Test
4.7.1.1.1.2.1. Targeted Test Market, 2021 - 2033 (USD Million)
4.7.1.1.1.3. Point of Care Molecular Diagnostics
4.7.1.1.1.3.1. Point of Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
4.8. Meningitis / CNS Infections
4.8.1. Meningitis / CNS Infections Market, 2021 - 2033 (USD Million)
4.9. Vector-Borne Infections
4.9.1. Vector-Borne Infections Market, 2021 - 2033 (USD Million)
4.9.1.1. Disease Type
4.9.1.1.1. Disease Type Market, 2021 - 2033 (USD Million)
4.9.1.1.1.1. Dengue
4.9.1.1.1.1.1. Dengue Market, 2021 - 2033 (USD Million)
4.9.1.1.1.2. Zika
4.9.1.1.1.2.1. Zika Market, 2021 - 2033 (USD Million)
4.9.1.1.1.3. Lyme Disease
4.9.1.1.1.3.1. Lyme Disease Market, 2021 - 2033 (USD Million)
4.9.1.1.1.4. West Nile Virus
4.9.1.1.1.4.1. West Nile Virus Market, 2021 - 2033 (USD Million)
4.9.1.1.1.5. Chikungunya
4.9.1.1.1.5.1. Chikungunya Market, 2021 - 2033 (USD Million)
4.9.1.1.1.6. Other Vector-Borne Infections
4.9.1.1.1.6.1. Other Vector-Borne Infections Market, 2021 - 2033 (USD Million)
Chapter 5. North America and Europe Infectious Disease Molecular Diagnostics Market: Test Category Business Analysis
5.1. Test Type Market Share, 2025 & 2033
5.2. Test Type Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Test Type, 2021 to 2033 (USD Million)
5.4. Syndromic Testing
5.4.1. Syndromic Testing Market, 2021 - 2033 (USD Million)
5.5. Targeted Test
5.5.1. Targeted In-Lab Testing Market, 2021 - 2033 (USD Million)
5.6. Point of Care Molecular Diagnostics
5.6.1. Point of Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
5.2. Test Type Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Test Type, 2021 to 2033 (USD Million)
5.4. Syndromic Testing
5.4.1. Syndromic Testing Market, 2021 - 2033 (USD Million)
5.5. Targeted Test
5.5.1. Targeted In-Lab Testing Market, 2021 - 2033 (USD Million)
5.6. Point of Care Molecular Diagnostics
5.6.1. Point of Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
Chapter 6. North America and Europe Infectious Disease Molecular Diagnostics Market: Customer Type Analysis
6.1. Customer Type Movement Analysis
6.2. Market Estimates & Forecast, by Customer Type (USD Million)
6.3. Hospital Laboratories
6.3.1. Hospital Laboratories Market, 2021 - 2033 (USD Million)
6.4. Reference Laboratories
6.4.1. Reference Laboratories Market, 2021 - 2033 (USD Million)
6.5. Academic Centers
6.5.1. Academic Centers Market, 2021 - 2033 (USD Million)
6.6. Regional Hospitals
6.6.1. Regional Hospitals Market, 2021 - 2033 (USD Million)
6.7. Children’s Hospital
6.7.1. Children’s Hospital Market, 2021 - 2033 (USD Million)
6.8. Others
6.8.1. Others Market, 2021 - 2033 (USD Million)
6.2. Market Estimates & Forecast, by Customer Type (USD Million)
6.3. Hospital Laboratories
6.3.1. Hospital Laboratories Market, 2021 - 2033 (USD Million)
6.4. Reference Laboratories
6.4.1. Reference Laboratories Market, 2021 - 2033 (USD Million)
6.5. Academic Centers
6.5.1. Academic Centers Market, 2021 - 2033 (USD Million)
6.6. Regional Hospitals
6.6.1. Regional Hospitals Market, 2021 - 2033 (USD Million)
6.7. Children’s Hospital
6.7.1. Children’s Hospital Market, 2021 - 2033 (USD Million)
6.8. Others
6.8.1. Others Market, 2021 - 2033 (USD Million)
Chapter 7. North America and Europe Infectious Disease Molecular Diagnostics Market Setting-Based Analysis
7.1. Setting-Based Movement Analysis
7.2. Market Estimates & Forecast, by Setting-Based (USD Million)
7.3. Central Laboratories
7.3.1. Central Laboratories Market, 2021 - 2033 (USD Million)
7.4. Near-Patient Settings
7.4.1. Near-Patient Settings Market, 2021 - 2033 (USD Million)
7.2. Market Estimates & Forecast, by Setting-Based (USD Million)
7.3. Central Laboratories
7.3.1. Central Laboratories Market, 2021 - 2033 (USD Million)
7.4. Near-Patient Settings
7.4.1. Near-Patient Settings Market, 2021 - 2033 (USD Million)
Chapter 8. North America and Europe Infectious Disease Molecular Diagnostics Market: Throughput Analysis
8.1. Throughput Movement Analysis
8.2. Market Estimates & Forecast, by Throughput (USD Million)
8.3. Low-Volume Laboratories
8.3.1. Low-Volume Laboratories Market, 2021 - 2033 (USD Million)
8.4. Mid-Volume Laboratories
8.4.1. Mid-Volume Laboratories Market, 2021 - 2033 (USD Million)
8.5. High-Volume Laboratories
8.5.1. High-Volume Laboratories Market, 2021 - 2033 (USD Million)
8.2. Market Estimates & Forecast, by Throughput (USD Million)
8.3. Low-Volume Laboratories
8.3.1. Low-Volume Laboratories Market, 2021 - 2033 (USD Million)
8.4. Mid-Volume Laboratories
8.4.1. Mid-Volume Laboratories Market, 2021 - 2033 (USD Million)
8.5. High-Volume Laboratories
8.5.1. High-Volume Laboratories Market, 2021 - 2033 (USD Million)
Chapter 9. North America and Europe Infectious Disease Molecular Diagnostics Market Algorithm-Based Analysis
9.1. Algorithm-Based Movement Analysis
9.2. Market Estimates & Forecast, by Algorithm-Based (USD Million)
9.3. Frontline Screening
9.3.1. Frontline Screening Market, 2021 - 2033 (USD Million)
9.4. Reflex/Algorithm-Driven Testing
9.4.1. Reflex/Algorithm-Driven Testing Market, 2021 - 2033 (USD Million)
9.5. Syndromic Testing (Algorithm-Based)
9.5.1. Syndromic Testing (Algorithm-Based) Market, 2021 - 2033 (USD Million)
9.6. Targeted Confirmation
9.6.1. Targeted Confirmation Market, 2021 - 2033 (USD Million)
9.2. Market Estimates & Forecast, by Algorithm-Based (USD Million)
9.3. Frontline Screening
9.3.1. Frontline Screening Market, 2021 - 2033 (USD Million)
9.4. Reflex/Algorithm-Driven Testing
9.4.1. Reflex/Algorithm-Driven Testing Market, 2021 - 2033 (USD Million)
9.5. Syndromic Testing (Algorithm-Based)
9.5.1. Syndromic Testing (Algorithm-Based) Market, 2021 - 2033 (USD Million)
9.6. Targeted Confirmation
9.6.1. Targeted Confirmation Market, 2021 - 2033 (USD Million)
Chapter 10. North America and Europe Infectious Disease Molecular Diagnostics Market: Regional Estimates & Trend Analysis
10.1. Regional Market Share Analysis, 2025 & 2033
10.2. Regional Market Dashboard
10.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
10.4. North America
10.4.1. North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
10.4.2. U.S.
10.4.2.1. Key Country Dynamics
10.4.2.2. Target Disease Prevalence
10.4.2.3. Regulatory Framework
10.4.2.4. Reimbursement Framework
10.4.2.5. U.S. North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.4.3. Canada
10.4.3.1. Key Country Dynamics
10.4.3.2. Target Disease Prevalence
10.4.3.3. Regulatory Framework
10.4.3.4. Reimbursement Framework
10.4.3.5. Canada North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.4.4. Mexico
10.4.4.1. Key Country Dynamics
10.4.4.2. Target Disease Prevalence
10.4.4.3. Regulatory Framework
10.4.4.4. Reimbursement Framework
10.4.4.5. Mexico North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.5. Europe
10.5.1. Europe North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.5.2. UK
10.5.2.1. Key Country Dynamics
10.5.2.2. Target Disease Prevalence
10.5.2.3. Regulatory Framework
10.5.2.4. Reimbursement Framework
10.5.2.5. Uk North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.5.3. Germany
10.5.3.1. Key Country Dynamics
10.5.3.2. Target Disease Prevalence
10.5.3.3. Regulatory Framework
10.5.3.4. Reimbursement Framework
10.5.3.5. Germany North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.5.4. France
10.5.4.1. Key Country Dynamics
10.5.4.2. Target Disease Prevalence
10.5.4.3. Regulatory Framework
10.5.4.4. Reimbursement Framework
10.5.4.5. France North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.5.5. Italy
10.5.5.1. Key Country Dynamics
10.5.5.2. Target Disease Prevalence
10.5.5.3. Regulatory Framework
10.5.5.4. Reimbursement Framework
10.5.5.5. Italy North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.5.6. Spain
10.5.6.1. Key Country Dynamics
10.5.6.2. Target Disease Prevalence
10.5.6.3. Regulatory Framework
10.5.6.4. Reimbursement Framework
10.5.6.5. Spain North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.5.7. Denmark
10.5.7.1. Key Country Dynamics
10.5.7.2. Target Disease Prevalence
10.5.7.3. Regulatory Framework
10.5.7.4. Reimbursement Framework
10.5.7.5. Denmark North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.5.8. Sweden
10.5.8.1. Key Country Dynamics
10.5.8.2. Target Disease Prevalence
10.5.8.3. Regulatory Framework
10.5.8.4. Reimbursement Framework
10.5.8.5. Sweden North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.5.9. Norway
10.5.9.1. Key Country Dynamics
10.5.9.2. Target Disease Prevalence
10.5.9.3. Regulatory Framework
10.5.9.4. Reimbursement Framework
10.5.9.5. Norway North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.2. Regional Market Dashboard
10.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
10.4. North America
10.4.1. North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
10.4.2. U.S.
10.4.2.1. Key Country Dynamics
10.4.2.2. Target Disease Prevalence
10.4.2.3. Regulatory Framework
10.4.2.4. Reimbursement Framework
10.4.2.5. U.S. North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.4.3. Canada
10.4.3.1. Key Country Dynamics
10.4.3.2. Target Disease Prevalence
10.4.3.3. Regulatory Framework
10.4.3.4. Reimbursement Framework
10.4.3.5. Canada North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.4.4. Mexico
10.4.4.1. Key Country Dynamics
10.4.4.2. Target Disease Prevalence
10.4.4.3. Regulatory Framework
10.4.4.4. Reimbursement Framework
10.4.4.5. Mexico North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.5. Europe
10.5.1. Europe North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.5.2. UK
10.5.2.1. Key Country Dynamics
10.5.2.2. Target Disease Prevalence
10.5.2.3. Regulatory Framework
10.5.2.4. Reimbursement Framework
10.5.2.5. Uk North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.5.3. Germany
10.5.3.1. Key Country Dynamics
10.5.3.2. Target Disease Prevalence
10.5.3.3. Regulatory Framework
10.5.3.4. Reimbursement Framework
10.5.3.5. Germany North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.5.4. France
10.5.4.1. Key Country Dynamics
10.5.4.2. Target Disease Prevalence
10.5.4.3. Regulatory Framework
10.5.4.4. Reimbursement Framework
10.5.4.5. France North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.5.5. Italy
10.5.5.1. Key Country Dynamics
10.5.5.2. Target Disease Prevalence
10.5.5.3. Regulatory Framework
10.5.5.4. Reimbursement Framework
10.5.5.5. Italy North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.5.6. Spain
10.5.6.1. Key Country Dynamics
10.5.6.2. Target Disease Prevalence
10.5.6.3. Regulatory Framework
10.5.6.4. Reimbursement Framework
10.5.6.5. Spain North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.5.7. Denmark
10.5.7.1. Key Country Dynamics
10.5.7.2. Target Disease Prevalence
10.5.7.3. Regulatory Framework
10.5.7.4. Reimbursement Framework
10.5.7.5. Denmark North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.5.8. Sweden
10.5.8.1. Key Country Dynamics
10.5.8.2. Target Disease Prevalence
10.5.8.3. Regulatory Framework
10.5.8.4. Reimbursement Framework
10.5.8.5. Sweden North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.5.9. Norway
10.5.9.1. Key Country Dynamics
10.5.9.2. Target Disease Prevalence
10.5.9.3. Regulatory Framework
10.5.9.4. Reimbursement Framework
10.5.9.5. Norway North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 11. Competitive Landscape
11.1. Participant Overview
11.2. Company Market Position Analysis
11.3. Company Categorization
11.4. Strategy Mapping
11.5. Company Profiles/Listing
11.5.1. BD
11.5.1.1. Overview
11.5.1.2. Financial Performance
11.5.1.3. Product Benchmarking
11.5.1.4. Strategic Initiatives
11.5.2. Diasorin S.P.A.
11.5.2.1. Overview
11.5.2.2. Financial Performance
11.5.2.3. Product Benchmarking
11.5.2.4. Strategic Initiatives
11.5.3. Abbott
11.5.3.1. Overview
11.5.3.2. Financial Performance
11.5.3.3. Product Benchmarking
11.5.3.4. Strategic Initiatives
11.5.4. QuidelOrtho Corporation
11.5.4.1. Overview
11.5.4.2. Financial Performance
11.5.4.3. Product Benchmarking
11.5.4.4. Strategic Initiatives
11.5.5. Danaher Corporation
11.5.5.1. Overview
11.5.5.2. Financial Performance
11.5.5.3. Product Benchmarking
11.5.5.4. Strategic Initiatives
11.5.6. Thermo Fisher Scientific Inc
11.5.6.1. Overview
11.5.6.2. Financial Performance
11.5.6.3. Product Benchmarking
11.5.6.4. Strategic Initiatives
11.5.7. Biomerieux SA
11.5.7.1. Overview
11.5.7.2. Financial Performance
11.5.7.3. Product Benchmarking
11.5.7.4. Strategic Initiatives
11.5.8. F. Hoffmann-La Roche Ltd.
11.5.8.1. Overview
11.5.8.2. Financial Performance
11.5.8.3. Product Benchmarking
11.5.8.4. Strategic Initiatives
11.5.9. QIAGEN
11.5.9.1. Overview
11.5.9.2. Financial Performance
11.5.9.3. Product Benchmarking
11.5.9.4. Strategic Initiatives
11.5.10. Seegene Inc.
11.5.10.1. Overview
11.5.10.2. Financial Performance
11.5.10.3. Product Benchmarking
11.5.10.4. Strategic Initiatives
11.5.11. Bosch Healthcare Solutions GmbH.
11.5.11.1. Overview
11.5.11.2. Financial Performance
11.5.11.3. Product Benchmarking
11.5.11.4. Strategic Initiatives
11.5.12. QuidelOrtho Corporation
11.5.12.1. Overview
11.5.12.2. Financial Performance
11.5.12.3. Product Benchmarking
11.5.12.4. Strategic Initiatives
11.5.13. Hologic, Inc.
11.5.13.1. Overview
11.5.13.2. Financial Performance
11.5.13.3. Product Benchmarking
11.5.13.4. Strategic Initiatives
11.5.14. Siemens Healthineers AG
11.5.14.1. Overview
11.5.14.2. Financial Performance
11.5.14.3. Product Benchmarking
11.5.14.4. Strategic Initiatives
11.2. Company Market Position Analysis
11.3. Company Categorization
11.4. Strategy Mapping
11.5. Company Profiles/Listing
11.5.1. BD
11.5.1.1. Overview
11.5.1.2. Financial Performance
11.5.1.3. Product Benchmarking
11.5.1.4. Strategic Initiatives
11.5.2. Diasorin S.P.A.
11.5.2.1. Overview
11.5.2.2. Financial Performance
11.5.2.3. Product Benchmarking
11.5.2.4. Strategic Initiatives
11.5.3. Abbott
11.5.3.1. Overview
11.5.3.2. Financial Performance
11.5.3.3. Product Benchmarking
11.5.3.4. Strategic Initiatives
11.5.4. QuidelOrtho Corporation
11.5.4.1. Overview
11.5.4.2. Financial Performance
11.5.4.3. Product Benchmarking
11.5.4.4. Strategic Initiatives
11.5.5. Danaher Corporation
11.5.5.1. Overview
11.5.5.2. Financial Performance
11.5.5.3. Product Benchmarking
11.5.5.4. Strategic Initiatives
11.5.6. Thermo Fisher Scientific Inc
11.5.6.1. Overview
11.5.6.2. Financial Performance
11.5.6.3. Product Benchmarking
11.5.6.4. Strategic Initiatives
11.5.7. Biomerieux SA
11.5.7.1. Overview
11.5.7.2. Financial Performance
11.5.7.3. Product Benchmarking
11.5.7.4. Strategic Initiatives
11.5.8. F. Hoffmann-La Roche Ltd.
11.5.8.1. Overview
11.5.8.2. Financial Performance
11.5.8.3. Product Benchmarking
11.5.8.4. Strategic Initiatives
11.5.9. QIAGEN
11.5.9.1. Overview
11.5.9.2. Financial Performance
11.5.9.3. Product Benchmarking
11.5.9.4. Strategic Initiatives
11.5.10. Seegene Inc.
11.5.10.1. Overview
11.5.10.2. Financial Performance
11.5.10.3. Product Benchmarking
11.5.10.4. Strategic Initiatives
11.5.11. Bosch Healthcare Solutions GmbH.
11.5.11.1. Overview
11.5.11.2. Financial Performance
11.5.11.3. Product Benchmarking
11.5.11.4. Strategic Initiatives
11.5.12. QuidelOrtho Corporation
11.5.12.1. Overview
11.5.12.2. Financial Performance
11.5.12.3. Product Benchmarking
11.5.12.4. Strategic Initiatives
11.5.13. Hologic, Inc.
11.5.13.1. Overview
11.5.13.2. Financial Performance
11.5.13.3. Product Benchmarking
11.5.13.4. Strategic Initiatives
11.5.14. Siemens Healthineers AG
11.5.14.1. Overview
11.5.14.2. Financial Performance
11.5.14.3. Product Benchmarking
11.5.14.4. Strategic Initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 North America Infectious Disease Molecular Diagnostics market, by country, 2021 - 2033 (USD Million)
Table 4 North America Infectious Disease Molecular Diagnostics market, by Application, 2021 - 2033 (USD Million)
Table 5 North America Infectious Disease Molecular Diagnostics market, by Test Category, 2021 - 2033 (USD Million)
Table 6 North America Infectious Disease Molecular Diagnostics market, by Customer Type, 2021 - 2033 (USD Million)
Table 7 North America Infectious Disease Molecular Diagnostics market Setting-based, 2021 - 2033 (USD Million)
Table 8 North America Infectious Disease Molecular Diagnostics market Throughput, 2021 - 2033 (USD Million)
Table 9 North America Infectious Disease Molecular Diagnostics market Algorithm-based, 2021 - 2033 (USD Million)
Table 10 U.S. Infectious Disease Molecular Diagnostics market, by Application, 2021 - 2033 (USD Million)
Table 11 U.S. Infectious Disease Molecular Diagnostics market, by Test Category, 2021 - 2033 (USD Million)
Table 12 U.S. Infectious Disease Molecular Diagnostics market, by Customer Type, 2021 - 2033 (USD Million)
Table 13 U.S. Infectious Disease Molecular Diagnostics market Setting-based, 2021 - 2033 (USD Million)
Table 14 U.S. Infectious Disease Molecular Diagnostics market Throughput, 2021 - 2033 (USD Million)
Table 15 U.S. Infectious Disease Molecular Diagnostics market Algorithm-based, 2021 - 2033 (USD Million)
Table 16 Canada Infectious Disease Molecular Diagnostics market, by Application, 2021 - 2033 (USD Million)
Table 17 Canada Infectious Disease Molecular Diagnostics market, by Test Category, 2021 - 2033 (USD Million)
Table 18 Canada Infectious Disease Molecular Diagnostics market, by Customer Type, 2021 - 2033 (USD Million)
Table 19 Canada Infectious Disease Molecular Diagnostics market Setting-based, 2021 - 2033 (USD Million)
Table 20 Canada Infectious Disease Molecular Diagnostics market Throughput, 2021 - 2033 (USD Million)
Table 21 Canada Infectious Disease Molecular Diagnostics market Algorithm-based, 2021 - 2033 (USD Million)
Table 22 Mexico Infectious Disease Molecular Diagnostics market, by Application, 2021 - 2033 (USD Million)
Table 23 Mexico Infectious Disease Molecular Diagnostics market, by Test Category, 2021 - 2033 (USD Million)
Table 24 Mexico Infectious Disease Molecular Diagnostics market, by Customer Type, 2021 - 2033 (USD Million)
Table 25 Mexico Infectious Disease Molecular Diagnostics market Setting-based, 2021 - 2033 (USD Million)
Table 26 Mexico Infectious Disease Molecular Diagnostics market Throughput, 2021 - 2033 (USD Million)
Table 27 Mexico Infectious Disease Molecular Diagnostics market Algorithm-based, 2021 - 2033 (USD Million)
Table 28 Europe Infectious Disease Molecular Diagnostics market, by country, 2021 - 2033 (USD Million)
Table 29 Europe Infectious Disease Molecular Diagnostics market, by Application, 2021 - 2033 (USD Million)
Table 30 Europe Infectious Disease Molecular Diagnostics market, by Test Category, 2021 - 2033 (USD Million)
Table 31 Europe Infectious Disease Molecular Diagnostics market, by Customer Type, 2021 - 2033 (USD Million)
Table 32 Europe Infectious Disease Molecular Diagnostics market Setting-based, 2021 - 2033 (USD Million)
Table 33 Europe Infectious Disease Molecular Diagnostics market Throughput, 2021 - 2033 (USD Million)
Table 34 Europe Infectious Disease Molecular Diagnostics market Algorithm-based, 2021 - 2033 (USD Million)
Table 35 UK Infectious Disease Molecular Diagnostics market, by Application, 2021 - 2033 (USD Million)
Table 36 UK Infectious Disease Molecular Diagnostics market, by Test Category, 2021 - 2033 (USD Million)
Table 37 UK Infectious Disease Molecular Diagnostics market, by Customer Type, 2021 - 2033 (USD Million)
Table 38 UK Infectious Disease Molecular Diagnostics market Setting-based, 2021 - 2033 (USD Million)
Table 39 UK Infectious Disease Molecular Diagnostics market Throughput, 2021 - 2033 (USD Million)
Table 40 UK Infectious Disease Molecular Diagnostics market Algorithm-based, 2021 - 2033 (USD Million)
Table 41 Germany Infectious Disease Molecular Diagnostics market, by Application, 2021 - 2033 (USD Million)
Table 42 Germany Infectious Disease Molecular Diagnostics market, by Test Category, 2021 - 2033 (USD Million)
Table 43 Germany Infectious Disease Molecular Diagnostics market, by Customer Type, 2021 - 2033 (USD Million)
Table 44 Germany Infectious Disease Molecular Diagnostics market Setting-based, 2021 - 2033 (USD Million)
Table 45 Germany Infectious Disease Molecular Diagnostics market Throughput, 2021 - 2033 (USD Million)
Table 46 Germany Infectious Disease Molecular Diagnostics market Algorithm-based, 2021 - 2033 (USD Million)
Table 47 France Infectious Disease Molecular Diagnostics market, by Application, 2021 - 2033 (USD Million)
Table 48 France Infectious Disease Molecular Diagnostics market, by Test Category, 2021 - 2033 (USD Million)
Table 49 France Infectious Disease Molecular Diagnostics market, by Customer Type, 2021 - 2033 (USD Million)
Table 50 France Infectious Disease Molecular Diagnostics market, by Setting-based, 2021 - 2033 (USD Million)
Table 51 France Infectious Disease Molecular Diagnostics market, by Throughput, 2021 - 2033 (USD Million)
Table 52 France Infectious Disease Molecular Diagnostics market by Algorithm-based, 2021 - 2033 (USD Million)
Table 53 Italy Infectious Disease Molecular Diagnostics market, by Application, 2021 - 2033 (USD Million)
Table 54 Italy North America and Europe Infectious Disease Molecular Diagnostics market, by Test Category, 2021 - 2033 (USD Million)
Table 55 Italy Infectious Disease Molecular Diagnostics market, by Customer Type, 2021 - 2033 (USD Million)
Table 56 Italy Infectious Disease Molecular Diagnostics market Setting-based, 2021 - 2033 (USD Million)
Table 57 Italy Infectious Disease Molecular Diagnostics market Throughput, 2021 - 2033 (USD Million)
Table 58 Italy Infectious Disease Molecular Diagnostics market Algorithm-based, 2021 - 2033 (USD Million)
Table 59 Spain Infectious Disease Molecular Diagnostics market, by Application, 2021 - 2033 (USD Million)
Table 60 Spain Infectious Disease Molecular Diagnostics market, by Test Category, 2021 - 2033 (USD Million)
Table 61 Spain Infectious Disease Molecular Diagnostics market, by Customer Type, 2021 - 2033 (USD Million)
Table 62 Spain Infectious Disease Molecular Diagnostics market Setting-based, 2021 - 2033 (USD Million)
Table 63 Spain Infectious Disease Molecular Diagnostics market Throughput, 2021 - 2033 (USD Million)
Table 64 Spain Infectious Disease Molecular Diagnostics market Algorithm-based, 2021 - 2033 (USD Million)
Table 65 Norway Infectious Disease Molecular Diagnostics market, by Application, 2021 - 2033 (USD Million)
Table 66 Norway Infectious Disease Molecular Diagnostics market, by Test Category, 2021 - 2033 (USD Million)
Table 67 Norway Infectious Disease Molecular Diagnostics market, by Customer Type, 2021 - 2033 (USD Million)
Table 68 Norway Infectious Disease Molecular Diagnostics market Setting-based, 2021 - 2033 (USD Million)
Table 69 Norway Infectious Disease Molecular Diagnostics market Throughput, 2021 - 2033 (USD Million)
Table 70 Norway Infectious Disease Molecular Diagnostics market Algorithm-based, 2021 - 2033 (USD Million)
Table 71 Denmark Infectious Disease Molecular Diagnostics market, by Application, 2021 - 2033 (USD Million)
Table 72 Denmark Infectious Disease Molecular Diagnostics market, by Test Category, 2021 - 2033 (USD Million)
Table 73 Denmark Infectious Disease Molecular Diagnostics market, by Customer Type, 2021 - 2033 (USD Million)
Table 74 Denmark Infectious Disease Molecular Diagnostics market Setting-based, 2021 - 2033 (USD Million)
Table 75 Denmark Infectious Disease Molecular Diagnostics market Throughput, 2021 - 2033 (USD Million)
Table 76 Denmark Infectious Disease Molecular Diagnostics market Algorithm-based, 2021 - 2033 (USD Million)
Table 77 Sweden Infectious Disease Molecular Diagnostics market, by Application, 2021 - 2033 (USD Million)
Table 78 Sweden Infectious Disease Molecular Diagnostics market, by Test Category, 2021 - 2033 (USD Million)
Table 79 Sweden Infectious Disease Molecular Diagnostics market, by Customer Type, 2021 - 2033 (USD Million)
Table 80 Sweden Infectious Disease Molecular Diagnostics market Setting-based, 2021 - 2033 (USD Million)
Table 81 Sweden Infectious Disease Molecular Diagnostics market Throughput, 2021 - 2033 (USD Million)
Table 82 Sweden Infectious Disease Molecular Diagnostics market Algorithm-based, 2021 - 2033 (USD Million)
Table 2 List of abbreviations
Table 3 North America Infectious Disease Molecular Diagnostics market, by country, 2021 - 2033 (USD Million)
Table 4 North America Infectious Disease Molecular Diagnostics market, by Application, 2021 - 2033 (USD Million)
Table 5 North America Infectious Disease Molecular Diagnostics market, by Test Category, 2021 - 2033 (USD Million)
Table 6 North America Infectious Disease Molecular Diagnostics market, by Customer Type, 2021 - 2033 (USD Million)
Table 7 North America Infectious Disease Molecular Diagnostics market Setting-based, 2021 - 2033 (USD Million)
Table 8 North America Infectious Disease Molecular Diagnostics market Throughput, 2021 - 2033 (USD Million)
Table 9 North America Infectious Disease Molecular Diagnostics market Algorithm-based, 2021 - 2033 (USD Million)
Table 10 U.S. Infectious Disease Molecular Diagnostics market, by Application, 2021 - 2033 (USD Million)
Table 11 U.S. Infectious Disease Molecular Diagnostics market, by Test Category, 2021 - 2033 (USD Million)
Table 12 U.S. Infectious Disease Molecular Diagnostics market, by Customer Type, 2021 - 2033 (USD Million)
Table 13 U.S. Infectious Disease Molecular Diagnostics market Setting-based, 2021 - 2033 (USD Million)
Table 14 U.S. Infectious Disease Molecular Diagnostics market Throughput, 2021 - 2033 (USD Million)
Table 15 U.S. Infectious Disease Molecular Diagnostics market Algorithm-based, 2021 - 2033 (USD Million)
Table 16 Canada Infectious Disease Molecular Diagnostics market, by Application, 2021 - 2033 (USD Million)
Table 17 Canada Infectious Disease Molecular Diagnostics market, by Test Category, 2021 - 2033 (USD Million)
Table 18 Canada Infectious Disease Molecular Diagnostics market, by Customer Type, 2021 - 2033 (USD Million)
Table 19 Canada Infectious Disease Molecular Diagnostics market Setting-based, 2021 - 2033 (USD Million)
Table 20 Canada Infectious Disease Molecular Diagnostics market Throughput, 2021 - 2033 (USD Million)
Table 21 Canada Infectious Disease Molecular Diagnostics market Algorithm-based, 2021 - 2033 (USD Million)
Table 22 Mexico Infectious Disease Molecular Diagnostics market, by Application, 2021 - 2033 (USD Million)
Table 23 Mexico Infectious Disease Molecular Diagnostics market, by Test Category, 2021 - 2033 (USD Million)
Table 24 Mexico Infectious Disease Molecular Diagnostics market, by Customer Type, 2021 - 2033 (USD Million)
Table 25 Mexico Infectious Disease Molecular Diagnostics market Setting-based, 2021 - 2033 (USD Million)
Table 26 Mexico Infectious Disease Molecular Diagnostics market Throughput, 2021 - 2033 (USD Million)
Table 27 Mexico Infectious Disease Molecular Diagnostics market Algorithm-based, 2021 - 2033 (USD Million)
Table 28 Europe Infectious Disease Molecular Diagnostics market, by country, 2021 - 2033 (USD Million)
Table 29 Europe Infectious Disease Molecular Diagnostics market, by Application, 2021 - 2033 (USD Million)
Table 30 Europe Infectious Disease Molecular Diagnostics market, by Test Category, 2021 - 2033 (USD Million)
Table 31 Europe Infectious Disease Molecular Diagnostics market, by Customer Type, 2021 - 2033 (USD Million)
Table 32 Europe Infectious Disease Molecular Diagnostics market Setting-based, 2021 - 2033 (USD Million)
Table 33 Europe Infectious Disease Molecular Diagnostics market Throughput, 2021 - 2033 (USD Million)
Table 34 Europe Infectious Disease Molecular Diagnostics market Algorithm-based, 2021 - 2033 (USD Million)
Table 35 UK Infectious Disease Molecular Diagnostics market, by Application, 2021 - 2033 (USD Million)
Table 36 UK Infectious Disease Molecular Diagnostics market, by Test Category, 2021 - 2033 (USD Million)
Table 37 UK Infectious Disease Molecular Diagnostics market, by Customer Type, 2021 - 2033 (USD Million)
Table 38 UK Infectious Disease Molecular Diagnostics market Setting-based, 2021 - 2033 (USD Million)
Table 39 UK Infectious Disease Molecular Diagnostics market Throughput, 2021 - 2033 (USD Million)
Table 40 UK Infectious Disease Molecular Diagnostics market Algorithm-based, 2021 - 2033 (USD Million)
Table 41 Germany Infectious Disease Molecular Diagnostics market, by Application, 2021 - 2033 (USD Million)
Table 42 Germany Infectious Disease Molecular Diagnostics market, by Test Category, 2021 - 2033 (USD Million)
Table 43 Germany Infectious Disease Molecular Diagnostics market, by Customer Type, 2021 - 2033 (USD Million)
Table 44 Germany Infectious Disease Molecular Diagnostics market Setting-based, 2021 - 2033 (USD Million)
Table 45 Germany Infectious Disease Molecular Diagnostics market Throughput, 2021 - 2033 (USD Million)
Table 46 Germany Infectious Disease Molecular Diagnostics market Algorithm-based, 2021 - 2033 (USD Million)
Table 47 France Infectious Disease Molecular Diagnostics market, by Application, 2021 - 2033 (USD Million)
Table 48 France Infectious Disease Molecular Diagnostics market, by Test Category, 2021 - 2033 (USD Million)
Table 49 France Infectious Disease Molecular Diagnostics market, by Customer Type, 2021 - 2033 (USD Million)
Table 50 France Infectious Disease Molecular Diagnostics market, by Setting-based, 2021 - 2033 (USD Million)
Table 51 France Infectious Disease Molecular Diagnostics market, by Throughput, 2021 - 2033 (USD Million)
Table 52 France Infectious Disease Molecular Diagnostics market by Algorithm-based, 2021 - 2033 (USD Million)
Table 53 Italy Infectious Disease Molecular Diagnostics market, by Application, 2021 - 2033 (USD Million)
Table 54 Italy North America and Europe Infectious Disease Molecular Diagnostics market, by Test Category, 2021 - 2033 (USD Million)
Table 55 Italy Infectious Disease Molecular Diagnostics market, by Customer Type, 2021 - 2033 (USD Million)
Table 56 Italy Infectious Disease Molecular Diagnostics market Setting-based, 2021 - 2033 (USD Million)
Table 57 Italy Infectious Disease Molecular Diagnostics market Throughput, 2021 - 2033 (USD Million)
Table 58 Italy Infectious Disease Molecular Diagnostics market Algorithm-based, 2021 - 2033 (USD Million)
Table 59 Spain Infectious Disease Molecular Diagnostics market, by Application, 2021 - 2033 (USD Million)
Table 60 Spain Infectious Disease Molecular Diagnostics market, by Test Category, 2021 - 2033 (USD Million)
Table 61 Spain Infectious Disease Molecular Diagnostics market, by Customer Type, 2021 - 2033 (USD Million)
Table 62 Spain Infectious Disease Molecular Diagnostics market Setting-based, 2021 - 2033 (USD Million)
Table 63 Spain Infectious Disease Molecular Diagnostics market Throughput, 2021 - 2033 (USD Million)
Table 64 Spain Infectious Disease Molecular Diagnostics market Algorithm-based, 2021 - 2033 (USD Million)
Table 65 Norway Infectious Disease Molecular Diagnostics market, by Application, 2021 - 2033 (USD Million)
Table 66 Norway Infectious Disease Molecular Diagnostics market, by Test Category, 2021 - 2033 (USD Million)
Table 67 Norway Infectious Disease Molecular Diagnostics market, by Customer Type, 2021 - 2033 (USD Million)
Table 68 Norway Infectious Disease Molecular Diagnostics market Setting-based, 2021 - 2033 (USD Million)
Table 69 Norway Infectious Disease Molecular Diagnostics market Throughput, 2021 - 2033 (USD Million)
Table 70 Norway Infectious Disease Molecular Diagnostics market Algorithm-based, 2021 - 2033 (USD Million)
Table 71 Denmark Infectious Disease Molecular Diagnostics market, by Application, 2021 - 2033 (USD Million)
Table 72 Denmark Infectious Disease Molecular Diagnostics market, by Test Category, 2021 - 2033 (USD Million)
Table 73 Denmark Infectious Disease Molecular Diagnostics market, by Customer Type, 2021 - 2033 (USD Million)
Table 74 Denmark Infectious Disease Molecular Diagnostics market Setting-based, 2021 - 2033 (USD Million)
Table 75 Denmark Infectious Disease Molecular Diagnostics market Throughput, 2021 - 2033 (USD Million)
Table 76 Denmark Infectious Disease Molecular Diagnostics market Algorithm-based, 2021 - 2033 (USD Million)
Table 77 Sweden Infectious Disease Molecular Diagnostics market, by Application, 2021 - 2033 (USD Million)
Table 78 Sweden Infectious Disease Molecular Diagnostics market, by Test Category, 2021 - 2033 (USD Million)
Table 79 Sweden Infectious Disease Molecular Diagnostics market, by Customer Type, 2021 - 2033 (USD Million)
Table 80 Sweden Infectious Disease Molecular Diagnostics market Setting-based, 2021 - 2033 (USD Million)
Table 81 Sweden Infectious Disease Molecular Diagnostics market Throughput, 2021 - 2033 (USD Million)
Table 82 Sweden Infectious Disease Molecular Diagnostics market Algorithm-based, 2021 - 2033 (USD Million)
List of Figures
Fig. 1 North America and Europe Infectious Disease Molecular Diagnostics segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value chain-based sizing & forecasting
Fig. 7 QFD modelling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Market snapshot
Fig. 10 Application and test category snapshot
Fig. 11 Customer type and setting-based snapshot
Fig. 12 Throughput and algorithm snapshot
Fig. 13 Competitive landscape snapshot
Fig. 14 Market trends & outlook
Fig. 15 U.S. seasonal infectious disease burden data (in '000), 2021-2026
Fig. 16 Heat map showing the detection frequency (%) of microbial target categories across the four BioFire FilmArray panels evaluated in this study (BCID2, PN Plus, ME and GI)
Fig. 17 Porter’s five force analysis
Fig. 18 PESTEL analysis
Fig. 19 North America and Europe infectious disease molecular diagnostics market: Application outlook and key takeaways
Fig. 20 North America and Europe infectious disease molecular diagnostics market: Application movement analysis
Fig. 21 Gastrointestinal infections market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 22 Syndromic test market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 23 Targeted test market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 24 Point of care molecular diagnostics test market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 25 Respiratory infection testing market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 26 Syndromic test market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 27 Targeted test market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 28 Point of care molecular diagnostics test market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 29 Hospital-acquired infections (HAIs) market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 30 Methicillin-Resistant Staphylococcus aureus (MRSA) market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 31 Clostridioides difficile Infection (CDI) market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 32 Carbapenem-Resistant Enterobacteriaceae (CRE) market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 33 Vancomycin-Resistant Enterococci (VRE) market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 34 Other Nosocomial Pathogens market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 35 Syndromic test market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 36 Targeted test market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 37 Point of care molecular diagnostics test market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 38 Bloodstream infections market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 39 Syndromic test market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 40 Targeted test market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 41 Point of care molecular diagnostics test market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 42 Meningitis/ CNS infections market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 43 Vector-borne infections market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 44 Dengue market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 45 Zika market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 46 Lyme Disease market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 47 West Nile Virus market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 48 Chikungunya market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 49 Other Vector-Borne Infections market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 50 North America and Europe infectious disease molecular diagnostics market: test category outlook and key takeaways
Fig. 51 North America and Europe infectious disease molecular diagnostics market: test category movement analysis
Fig. 52 Syndromic testing market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 53 Targeted in-lab testing market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 54 Point-of-Care (PoC) testing market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 55 North America and Europe infectious disease molecular diagnostics market: customer type outlook and key takeaways
Fig. 56 North America and Europe infectious disease molecular diagnostics market: customer type movement analysis
Fig. 57 Hospital laboratories market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 58 Reference laboratories market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 59 Academic centres market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 60 Regional hospitals market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 61 Children’s hospitals market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 62 Others market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 63 North America and Europe infectious disease molecular diagnostics market: setting-based outlook and key takeaways
Fig. 64 North America and Europe infectious disease molecular diagnostics market: setting-based movement analysis
Fig. 65 Central laboratories market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 66 Near-patient settings market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 67 North America and Europe infectious disease molecular diagnostics market: throughput outlook and key takeaways
Fig. 68 North America and Europe Infectious Disease Molecular Diagnostics market: throughput movement analysis
Fig. 69 Low-volume laboratories market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 70 Mid-volume laboratories market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 71 High-volume laboratories market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 72 North America and Europe infectious disease molecular diagnostics market: Algorithm-based outlook and key takeaways
Fig. 73 North America and Europe Infectious Disease Molecular Diagnostics market: algorithm-based movement analysis
Fig. 74 Frontline screening market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 75 Reflex/algorithm-driven testing market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 76 Syndromic testing (algorithm-based) market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 77 Targeted confirmation market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 78 North America and Europe infectious disease molecular diagnostics market revenue, by region, 2025 & 2033 (USD Million)
Fig. 79 Regional market place: Key takeaways
Fig. 80 North America infectious disease molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 81 Key country dynamics
Fig. 82 U.S. infectious disease molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 83 Key country dynamics
Fig. 84 Canada infectious disease molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 85 Mexico infectious disease molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 86 Rest of the Europe infectious disease molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 87 Key company categorization
Fig. 88 Company market share, 2025
Fig. 89 Strategy mapping
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value chain-based sizing & forecasting
Fig. 7 QFD modelling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Market snapshot
Fig. 10 Application and test category snapshot
Fig. 11 Customer type and setting-based snapshot
Fig. 12 Throughput and algorithm snapshot
Fig. 13 Competitive landscape snapshot
Fig. 14 Market trends & outlook
Fig. 15 U.S. seasonal infectious disease burden data (in '000), 2021-2026
Fig. 16 Heat map showing the detection frequency (%) of microbial target categories across the four BioFire FilmArray panels evaluated in this study (BCID2, PN Plus, ME and GI)
Fig. 17 Porter’s five force analysis
Fig. 18 PESTEL analysis
Fig. 19 North America and Europe infectious disease molecular diagnostics market: Application outlook and key takeaways
Fig. 20 North America and Europe infectious disease molecular diagnostics market: Application movement analysis
Fig. 21 Gastrointestinal infections market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 22 Syndromic test market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 23 Targeted test market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 24 Point of care molecular diagnostics test market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 25 Respiratory infection testing market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 26 Syndromic test market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 27 Targeted test market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 28 Point of care molecular diagnostics test market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 29 Hospital-acquired infections (HAIs) market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 30 Methicillin-Resistant Staphylococcus aureus (MRSA) market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 31 Clostridioides difficile Infection (CDI) market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 32 Carbapenem-Resistant Enterobacteriaceae (CRE) market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 33 Vancomycin-Resistant Enterococci (VRE) market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 34 Other Nosocomial Pathogens market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 35 Syndromic test market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 36 Targeted test market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 37 Point of care molecular diagnostics test market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 38 Bloodstream infections market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 39 Syndromic test market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 40 Targeted test market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 41 Point of care molecular diagnostics test market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 42 Meningitis/ CNS infections market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 43 Vector-borne infections market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 44 Dengue market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 45 Zika market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 46 Lyme Disease market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 47 West Nile Virus market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 48 Chikungunya market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 49 Other Vector-Borne Infections market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 50 North America and Europe infectious disease molecular diagnostics market: test category outlook and key takeaways
Fig. 51 North America and Europe infectious disease molecular diagnostics market: test category movement analysis
Fig. 52 Syndromic testing market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 53 Targeted in-lab testing market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 54 Point-of-Care (PoC) testing market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 55 North America and Europe infectious disease molecular diagnostics market: customer type outlook and key takeaways
Fig. 56 North America and Europe infectious disease molecular diagnostics market: customer type movement analysis
Fig. 57 Hospital laboratories market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 58 Reference laboratories market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 59 Academic centres market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 60 Regional hospitals market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 61 Children’s hospitals market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 62 Others market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 63 North America and Europe infectious disease molecular diagnostics market: setting-based outlook and key takeaways
Fig. 64 North America and Europe infectious disease molecular diagnostics market: setting-based movement analysis
Fig. 65 Central laboratories market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 66 Near-patient settings market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 67 North America and Europe infectious disease molecular diagnostics market: throughput outlook and key takeaways
Fig. 68 North America and Europe Infectious Disease Molecular Diagnostics market: throughput movement analysis
Fig. 69 Low-volume laboratories market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 70 Mid-volume laboratories market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 71 High-volume laboratories market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 72 North America and Europe infectious disease molecular diagnostics market: Algorithm-based outlook and key takeaways
Fig. 73 North America and Europe Infectious Disease Molecular Diagnostics market: algorithm-based movement analysis
Fig. 74 Frontline screening market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 75 Reflex/algorithm-driven testing market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 76 Syndromic testing (algorithm-based) market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 77 Targeted confirmation market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 78 North America and Europe infectious disease molecular diagnostics market revenue, by region, 2025 & 2033 (USD Million)
Fig. 79 Regional market place: Key takeaways
Fig. 80 North America infectious disease molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 81 Key country dynamics
Fig. 82 U.S. infectious disease molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 83 Key country dynamics
Fig. 84 Canada infectious disease molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 85 Mexico infectious disease molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 86 Rest of the Europe infectious disease molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 87 Key company categorization
Fig. 88 Company market share, 2025
Fig. 89 Strategy mapping
Companies Mentioned
- BD
- Diasorin S.P.A.
- Abbott
- QuidelOrtho Corporation
- Danaher Corporation
- Thermo Fisher Scientific Inc
- Biomerieux SA
- F. Hoffmann-La Roche Ltd.
- QIAGEN
- Seegene Inc.
- Bosch Healthcare Solutions GmbH
- QuidelOrtho Corporation
- Hologic, Inc.
- Siemens Healthineers AG
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | May 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 6.09 Billion |
| Forecasted Market Value ( USD | $ 10.77 Billion |
| Compound Annual Growth Rate | 7.4% |
| Regions Covered | Europe, North America |
| No. of Companies Mentioned | 14 |
